Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Boston, MA, June 3, 2013 (GLOBE NEWSWIRE) -- Inform Genomics, Inc., a private company focused on developing novel platforms of genomic-based personalized medicine products for cancer supportive care, presented the biologic validity of its lead platform product, OnPART™, on Saturday June 1st during the Patient Care Session at the 2013 ASCO meeting. This poster, entitled “From Bayesian Modeling to Genomic Mapping: Biologic Validity of Predictive Single Nucleotide Polymorphism Networks for Chemotherapy Related Side Effects,” highlights the discovery by scientists at Inform Genomics of Bayesian Single Nucleotide Polymorphism (SNP) networks that were highly predictive for 6 common side effects of chemotherapy including: diarrhea, nausea and vomiting, oral mucositis, fatigue, cognitive dysfunction and peripheral neuropathy. To validate the accuracy of OnPART™, each unique and proprietary SNP network was mapped to the genome and associated biologic pathways.
Help employers find you! Check out all the jobs and post your resume.
